Anti-programmed death 1 antibody in the treatment of coexistent Mycobacterium fortuitum and lung cancer: A case report

doi:10.12998/wjcc.v10.i12.3801

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3270)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

194

WORD

HTML

2117

Figures (1-3)

216

Sum=2601

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

200

Download

469

Sum=669

Apr 26, 2022 (publication date) through Jul 21, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Apr 26, 2022; 10(12): 3801-3807
Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3801

Full Size Figure Download Figure

Figure 1 Expression of programmed death ligand 1 (immunohistochemical staining, Dako 22C3). A: Positive controls × 200; B: Negative controls × 200; C: Tumor samples hematoxylin and eosin × 100; D: Tumor samples immunohistochemistry × 200.

Citation: Zhang CC, Chen P. Anti-programmed death 1 antibody in the treatment of coexistent Mycobacterium fortuitum and lung cancer: A case report. World J Clin Cases 2022; 10(12): 3801-3807
URL: https://www.wjgnet.com/2307-8960/full/v10/i12/3801.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i12.3801